Cardiometabolic Complications

Obesity drives cardiovascular and metabolic complications with multiple GLP-1 outcome trials reshaping practice. The session covers SELECT cardiovascular outcomes, STEP-HFpEF and HFpEF subtypes, FLOW renal outcomes, hypertension control in obesity, MASH coexistence and combined management, OSA management with GLP-1 (SURMOUNT-OSA), and the integration of cardiology, nephrology and obesity care. Discussion addresses the CKM (cardiovascular-kidney-metabolic) syndrome framework, atrial fibrillation in obesity, dyslipidemia management beyond LDL, the role of GLP-1 in NASH and cirrhosis, dialysis in obesity, and the cost-effectiveness of GLP-1 across cardiometabolic indications.